US 10,765,720 B2 · Composition for preventing or treating hyperoxia-induced lung injury comprising WKYMVm peptide as an active ingredient

Abstract

A composition for alleviating, preventing, or treating hyperoxia-induced lung injury, the composition including the WKYMVm peptide as an active ingredient is described. The composition has an effect of increasing FPR2 activation and ERK phosphorylation, and also has an effect of improving alveolarization and angiogenesis in hyperoxia-induced lung injury models, and thus the composition is anticipated to be usefully used for the alleviation, prevention, or treatment of hyperoxia-induced lung injury, particularly bronchopulmonary dysplasia.

Claims10

Dependent claims

A method of treating hyperoxia-induced lung injury comprising:

administering to a subject in need thereof an effective amount of a WKYMVm peptide, the WKYMVm peptide comprising the sequence of SEQ ID NO:
1,
wherein the hypoxia-induced lung injury is bronchopulmonary dysplasia, and
wherein the effective amount of the WKYMVm is from 1-100 μM.

1 more element

Dependencies are inferred from the claim text.

Facts

Application

16/207,441Filed 3 Dec 2018

Priority

KR 10-2017-01648804 Dec 2017

Published

US 2019/0192613 A127 Jun 2019

Granted

8 Sep 2020

Term ends

Not estimatedThe source records don’t support an estimate.

Classification5 codes

A61K 38/08
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof: peptides having 5 to 11 amino acids
A61P 11/00
Drugs for disorders of the respiratory system
A61P 29/00
Non-central analgesic, antipyretic or antiinflammatory agents
A61K
Medicines and medical preparations

Composition for preventing or treating hyperoxia-induced lung injury comprising WKYMVm peptide as an active ingredient

Life of this patent

Composition for preventing or treating hyperoxia-induced lung injury comprising WKYMVm peptide as an active ingredient

Life of this patent

Abstract

Claims10